Fungal infection in surgical patients

American Journal of Surgery

Volumn 171, Issue 3, 1996, Pages 374-382

  Dean, David A ^a   Burchard, Kenneth W ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; DIPHENHYDRAMINE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; PARACETAMOL;

ANTIFUNGAL ACTIVITY; BLOOD TOXICITY; BURN; CANDIDA; CLINICAL TRIAL; CRITICAL ILLNESS; FEVER; GYNECOMASTIA; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PARENTERAL NUTRITION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RIGOR; RISK FACTOR; TOPICAL DRUG ADMINISTRATION; TORULOPSIS; VOMITING;

EID: 0029967489     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(97)89647-X     Document Type: Article

References (100)

1. Pfaller MA. Infection control: opportunistic fungal infections, the increasing importance of Candida species. Infect Control Hosp Epidemiol. 1989;10:270.
2. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992;15:414-421.
3. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989;2:379-390.
4. Krause W, Matheis H, Wulf K. Fungemia and funguria after oral administration of Candida albicans. Lancet. 1969;1:598.
5. Hickey WF, Sommerville LH, Schoen FJ. Disseminated Candida glabrata: a report of a uniquely severe infection and a literature review. Am J Clin Pathol. 1983;80:724-727.
6. Parker JC, McClosky JJ, Knauer KA. Pathologic features of human candidiasis: a common deep mycosis of the brain, heart, and kidney in the altered host. Am J Clin Pathol. 1976;65:991-1000.
7. Burchard KW, Minor LB, Slotman GJ, Gann DS. Fungal sepsis in surgical patients. Arch Surg. 1983;118:217-221.
8. Dyess DL, Garrison RN, Fry DE. Candida sepsis: implications of polymicrobial blood-borne infection. Arch Surg. 1985;120:345-348.
9. Eubanks PJ, Virgilio CD, Klein S, Bongard F. Candida sepsis in surgical patients. Am J Surg. 1993;166:617-620.
10. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 1985;7:646-655.
11. Horan T, Culver D, Jarvis W. Pathogens causing nosocomial infections: preliminary data from the national nosocomial infections surveillance system. Antimicrob Newslet. 1988;5.
12. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med. 1989;91(suppl 3B):86S-89S.
13. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 1993;167:1247-1251.
14. Wey SB, Mori M, Pfaller MA. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642.
15. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med. 1989;149:2349-2353.
16. Brawner DL, Cutler JE. Variability in expression of cell surface antigens of Candida albicans during morphogenesis. Infect Immun. 1986;51:337.
17. Diamond RD, Clark RA, Haudenschild CC. Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. J Clin Invest. 1980;66:908.
18. Diamond RD, Oppenheim F, Nakagawa T, et al. Properties of a product of Candida albicans hyphae and pseudohyphae that inhibits contact between the fungi and human neutrophils in vitro, J Immunol. 1980;125:2797.
19. Edwards JE, Mayer CL, Filler SG, et al. Cell extracts of Candida albicans block adherence of die organisms to endothelial cells. Infect Immun. 1992;60:3087-3091.
20. Hughes WT. Systemic candidiasis: a study of 109 fatal cases. Pediatr Infect Dis. 1982;1:11-18.
21. Lewis JH, Patel HR, Zimmerman HJ. The spectrum of hepatic candidiasis. Hepatology. 1982;2:476-487.
22. Wingard JR, Merz WG, Saral R. Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med. 1979;91:539-543.
23. Bodey GP, Lano M. Skin lesions associated with disseminated candidiasis. JAMA. 1974;222:1466-1468.
24. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality. Am J Med. 1981;71:363-370.
25. Plouffe JF, Brown DG, Silva J, et al. Nosocomial outbreak of Candida parapsilosis fungemia related to intravenous infusions. Arch Intern Med. 1977;137:1686-1689.
26. Atkinson JB, Connor DH, Robinowitz M, et al. Cardiac fungal infections: review of autopsy findings in 60 patients. Hum Pathol. 1984;15:935-942.
27. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. NEJM. 1992;325:1274-1277.
28. McGinnis MR, Ajello L, Beneke ES, et al. Taxonomic and nomenclature evaluation of the genera Candida and Torulopsis. J Clin Microbiol. 1984;20:813-814.
29. Kauffman CA, Tan JS. Torulopsis glabrata renal infection. Am J Med. 1974;57:217-224.
30. Seelig MS. The role of antibiotics in the pathogenesis of Candida infections. Am J Med. 1966;40:887.
31. Isenberg HD, Pisano MA, Carito SL, Berkman JS, Factors leading to overt monilial disease: preliminary studies on the ecological relationship between Candida albicans and intestinal bacteria. Antibiot Chemother. 1960;10:253.
32. Stone HH, Kolb LD, Currie CA, et al. Candida sepsis: pathogenesis and principles of treatment. Ann Surg. 1974;179:697-711.
33. Kennedy MJ, Volz PA. Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by antagonism. Infect Immun. 1985;49:654-663.
34. Samonis G, Gikas A, Toludis P, et al. Prospective study of the impact of broad-spectrum antibiotics on yeast flora of the human gut. Eur J Clin Microbiol Infect Dis. 1994;13:665-667.
35. Volkheimer G, Schultz FH. The phenomenon of persorption. Digestion. 1968;1:213.
36. Hiatt JR, Kobayashi MR, Doty JE, Ramming KP. Acalculous Candida cholecystitis: a complication of critical surgical illness. Am Surg. 1991;57:825-829.
37. Howard JM, Bieluch VM. Pancreatic abscess secondary to Candida albicans. Pancreas. 1989;4:120.
38. Anaissie E, Solomkin JS. Fungal infection. In: Meakins JL, ed. Surgical Infections: Diagnosis and Treatment. Vol. 1. New York: Scientific American; 1994:411-425.
39. Gogos CA. Effect of different types of total parenteral nutrition on T-lymphocyte subpopulations and NK cells. Am J Clin Nutr. 1990;51: 119-122.
40. Hennessey PJ, Black CT, Androgsy RJ. Glycosylation of immunoglobulin G impairs complement fixation. J Parenter Enter Nutr. 1991;15:60-64.
41. Palmbland J. Intravenous lipid emulsions and host defense: a critical review. Clin Nutr. 1991;10:303-308.
42. Shou J, Lappin J, Daly JM. Impairment of pulmonary macrophage function with total parenteral nutrition. Ann Surg. 1994;3:291-297.
43. Alverdy J, Aoys E, Weiss-Carrington P, Burk DA. The effect of glutamine-enriched TPN on gut immune cellularity. J Surg Res. 1992;52:34-39.
44. Shou J, Lappin J, Minnard E, Daly JM. TPN, bacterial translocation and host immune function. Am J Surg. 1994;167:145-150.
45. Alverdy J, Aoys E, Moss GS. Total parenteral nutrition promotes bacterial translocation from the gut. Surgery. 1988;104:185-190.
46. Alexander JW, Ogle CK, Stinnet JD, et al. A sequential prospective analysis of immunologic abnormalities and infection following severe thermal injury. Ann Surg. 1978;188:809-816.
47. Bjerknes R, Vindenes H, Pitkanen J, et al. Altered polymorphonuclear neutrophilic granulocyte functions in patients with large burns. J Trauma. 1989;29:847-855.
48. Bradley JA, Hamilton DNH, Brown MW, et al. Cellular defense in the critically ill surgical patient. Crit Care Med. 1984;12:565-570.
49. McLoughlin GA, Wu AV, Saporoschetz I, et al. Correlation between anergy and a circulating immunosuppressive factor following major surgical trauma. Ann Surg. 1979;190:297-304.
50. Scovill WA, Saba TM. Humoral recognition deficiency in etiology of reticuloendothelial depression induced by surgery. Ann Surg. 1973;178:59.
51. Kirkpatrick CH. Host factors in defense against fungal infection. Am J Infect. 1984;77(suppl 4D):1-12.
52. Diamond RD. Immune response to fungal infection. Rev Infect Dis. 1989;11(suppl 7):S1600-S1604.
53. Schaffner A, Davis CE, Schaffner T, et al. In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest. 1986;78:511.
54. Pruitt BA Jr., Goodwin CW, Pruitt SK. Bums: including cold, chemical, and electrical injuries. In: Sabiston DC Jr., ed. Textbook of Surgery: The Biological Basis of Modem Surgical Practice. 14th ed. Philadelphia: WB Saunders; 1991.
55. Calvano SE, DeRiesthal HF, Marano MA, et al. The decrease in peripheral blood CD4+ and T cells following thermal injury in humans can be accounted for by a concomitant decrease in suppressor-inducer CD4+ and T cells as assessed using anti-CD45R. Clin Immunol Immunopathol. 1988;47:164.
56. Gadd MA, Hansbrough JF, Hoyt DB, et al. Defective T-cell surface antigen expression after mitogen stimulation: an index of lymphocyte dysfunction after controlled murine injury. Ann Surg. 1989;209:112.
57. Constantian MB. Association of sepsis with an immunosuppressive polypeptide in the serum of bum patients. Ann Surg. 1978;188: 209.
58. Savino JA, Agarwal N, Wry P, et al. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in non transplant/non burned critically ill surgical and trauma patients. J Trauma. 1994;36:20-26.
59. Sherertz RJ, Raad II, Belani A, et al. Three-year experience with sonicated vascular catheter cultures in a microbiology laboratory. J Clin Microbiol. 1990;28:76.
60. Burchard KW. Fungal sepsis. Infect Dis Clin North Am. 1992;6:677-692.
61. Solomkin JS, Flohr AM, Simmons RL, Indications for therapy for fungemia in postoperative patients. Arch Surg. 1982;117:1272-1275.
62. Gaines JD, Remington JS. Disseminated candidiasis in surgical patients. Surgery. 1972;72:730.
63. Geha DJ, Roberts GT. Laboratory detection of fungemia. Clin Lab Med. 1994;14:83-97.
64. Bayard RW. Arterial blood cultures in disseminated fungal disease. Pediatr Infect Dis J. 1989;8:728-729.
65. Kujath P, Lerch K, Dammrich J. Fluconazole monitoring in Candida peritonitis based on histological control. Mycoses. 1990;33: 441-448.
66. Rutledge R, Mandel SR, Wild RE. Candida sepsis: insignificant contaminant or pathologic species. Am Surg. 1986;52:299.
67. Konnes RJ, Cutitar M, Burchard KW. Perforated peptic ulcer, determinants of morbidity and mortality. Am Surg. 1990;56:280-284.
68. Ikeda K, Yamashita J, Fujisawa H, et al. Cerebral granuloma and meningitis caused by Candida albicans useful monitoring of mannan antigen in cerebrospinal fluid. Neurosurgery. 1990;26:860-865.
69. Kozinn PJ, Taschdjian CL, Kodsi BE, et al. Diagnosis of systemic and visceral candidosis. Can Med Assoc J. 1982;126:1386-1390.
70. Podzorski RP, Herron MJ, Fast DJ, et al. Pathogenesis of candidiasis. Arch Surg. 1989;124:1290-1294.
71. Walsh TJ, Hathorn JW, Sobel JD, et al. Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis. NEJM. 1991;324:1026-1031.
72. Rosemurgy AS, Sweeney JF, Albrink MH, et al. Implications of Candida titers in injured adults. Contemp Surg. 1993;42:327-332.
73. Cabezudo I, Pfaller M, Gerarden T, et al. Value of the Cand-Tec Candida antigen assay in the diagnosis and therapy of systemic candidiasis in the high-risk patients. Eur J Clin Microbiol Infect Dis. 1989;8:770-777.
74. Pfaller MA, Cabezudo I, Buschelman B, et al. Value of the Hybritech ICON Candida assay in the diagnosis of invasive candidiasis in high-risk patients. Diagn Microbiol Infect Dis. 1993;16:53-60.
75. Jarowski CI, Fialk MA, Murray HH, et al. Fever, rash and muscle tenderness: a distinctive clinical presentation of disseminated candidiasis. Arch Intern Med. 1978;138:544-546.
76. Kressel B, Szewczyk C, Tuazon CV. Early clinical resolution of disseminated candidiasis by muscle and skin biopsy. Arch Intern Med. 1978;138:429-431.
77. Donahue SP, Graven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology. 1994;101:1302-1309.
78. Slotman GJ, Shapiro E, Moffa SM. Fungal sepsis: multisite colonization versus fungemia. Am Surg. 1994;60:107-113.
79. Van den Bossche H, Willensens G, Marichal P. Anti-Candida drugs. The biological basis for their activity. Crit Rev Microbiol. 1987;15:57-72.
80. Brajtburg J, Powderly WG, Kobayashi GS, et al. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 1989;33:362.
81. Solomkin JS, Flohr A, Simmons RL. Candida infections in surgical patients: dose requirements and toxicity of amphotericin B. Ann Surg. 1982;195:177-185.
82. Craven PC, Ludden TM, Drutz DJ, et al. Excretion pathways of amphotericin B. J Infect Dis. 1979;140:329-341.
83. Patterson TF, Andriole VT. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol. 1989;25(suppl 2):S63-S68.
84. Stone HH. Studies in the pathogenesis, diagnosis and treatment of Candida sepsis in children. J Pediatr Surg. 1974;9:127-132.
85. Degregorio MN, Lee WM, Reis RA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer, 1982;50:2780-2784.
86. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. NEJM. 1994;330:263-272.
87. Van Der Mer JW, Kewning JJ, Scheijgrong HW, et al. The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother. 1980;6:552-554.
88. Slotman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg. 1987;122:147-150.
89. Bodey GP. Azole antifungal agents. Clin Infect Dis. 1992;14(suppl 1):S161-S169.
90. Brammer KW, Farrow PR, Falkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(suppl 3):S318-S326.
91. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow patients. Antimicrob Agents Chemother, 1993;37: 1847-1849.
92. Kujath P, Lerch K, Kcendorfer P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection. 1993;21:376-382.
93. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. NEJM. 1994;331:1325-1330.
94. Bodey GP, Anaissie EJ, Elting LS, et al. Antifungal prophylaxis during remission therapy for acute leukemia, fluconazole versus amphotericin B. Cancer. 1994;73:2099-2106.
95. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. NEJM. 1992;326:845-851.
96. Vinsant GO, Todd J, Fallon W. Reduction of Candida infections in the high risk trauma patient. Presented as a poster paper at the American College of Surgeons Clinical Congress. 1993; San Francisco, California.
97. Pierone G. Candiduria in hospitalized patients. Infect Surg. 1990; May:C-H.
98. Nassoura Z, Ivatury RR, Simon RJ, et al. Candiduria as an early marker of disseminated infection in critically ill surgical patients: the role of fluconazole therapy. J Trauma. 1993;35:290-295.
99. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994; 220:751-758.
100. Edwards JE, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in non-neutropenic patients. Clin Infect Dis. 1992;14(suppl 1):S106.